#durvalumab
LightNews LightNews
stephenvliu.bsky.social
Durvalumab now FDA approved for limited stage #SCLC based on the phase III ADRIATIC trial showing a PFS and an OS benefit (HR 0.73) with 2y of durvalumab after completion of definitive chemoradiation (avoid concurrent use). #LCSM #OncSky

www.targetedonc.com/view/durvalu....
Durvalumab Wins FDA Approval in Limited-Stage Small Cell Lung Cancer
The approval of durvalumab, based on data from the phase 3 ADRIATIC study, offers a new standard of care for patients with limited-stage small cell lung cancer.
www.targetedonc.com
December 4, 2024 at 11:51 PM
oncodaily.bsky.social
FDA approves durvalumab for limited-stage small cell lung cancer

oncodaily.com/blog/fda-198...

fda.gov

#Cancer #Durvalumab #EuropeanMedicinesAgency #FDA #Health #OncoDaily #Oncology #SmallCellLungCancer
FDA approves durvalumab for limited-stage small cell lung cancer - OncoDaily
FDA approves durvalumab for limited-stage small cell lung cancer / Australian Therapeutic Goods Administration, Brazilian Health Regulatory Agency, Byoung
oncodaily.com
December 7, 2024 at 5:55 PM
samillingworth.com
💊 Stomach cancer drug cuts death risk

In a trial of 948 people with stomach cancer in 20 countries, adding durvalumab to chemotherapy before and after surgery cut the risk of dying by 22% versus chemo alone.

🔗 www.thelancet.com/journals/lan...

#Cancer #Oncology #Science 🧪
Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival...
Perioperative durvalumab plus FLOT improved overall survival versus placebo plus FLOT and is a new standard treatment option for patients with resectable gastric or gastro-oesophageal junction adenoca...
www.thelancet.com
September 11, 2026 at 4:53 AM
drjnaidoo.bsky.social
FDA approves durvalumab for LS small cell lung cancer based on Ph III ADRIATIC trial:

- PFS benefit (HR 0.76)
- OS benefit (HR 0.73)
- 2 yrs durvalumab after definitive chemoRT
- currently available in 🇮🇪 on EAP

www.fda.gov/drugs/resour...

#MedSky #OncSky #LcSM @oncoalert.bsky.social
FDA approves durvalumab for limited-stage small cell lung cancer
On December 4, 2024, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) for limited-stage small cell lung cancer (LS-SCLC).
www.fda.gov
December 5, 2024 at 7:58 AM
oncodaily.bsky.social
Durvalumab (Imfinzi): Uses in Cancer, Side effects, Dosage, Expectations and More

oncodaily.com/drugs/durval...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Durvalumab #Imfinzi
Durvalumab (Imfinzi): Uses in Cancer, Side effects, Dosage, Expectations and More - OncoDaily
Explore Durvalumab (Imfinzi): how it works, cancer types it treats, dosage, side effects, clinical trial insights, and what patients can expect.
oncodaily.com
April 24, 2025 at 10:11 PM
oncodaily.bsky.social
MATTERHORN – FLOT plus durvalumab will become the new standard of care in the preoperative setting for gastroesophageal cancer🎗️

MATTERHORN trial combining FLOT chemotherapy with durvalumab significantly improved EFS in the perioperative setting of gastric and GEJ cancers🚨
March 7, 2025 at 8:33 PM
stephenvliu.bsky.social
Phase II study of durvalumab + tremelimumab + chemotherapy in #EGFR NSCLC post TKI @jtoonline.bsky.social (n=100). In T790M- (including 1L osi), RR 31% (none in PDL1 negative), DOR 9.5m, PFS 6.5m. In T790M+ (with 2L osi), RR 21%, DOR 6.3m, PFS 4.9m. Modest activity.

www.jtocrr.org/article/S266...
Durvalumab, tremelimumab and platinum chemotherapy in EGFR mutation positive non-small cell lung cancer - an open label phase 2 trial (ILLUMINATE)
EGFR-mutant NSCLC is associated with low mutation burden and low levels of PD-L1 expression. We conducted a phase 2 trial to determine the efficacy of durvalumab, tremelimumab and platinum-pemetrexed ...
www.jtocrr.org
November 25, 2024 at 11:42 AM
oncolojo.bsky.social
@drjnaidoo.bsky.social on the limited stage small cell space and the excitement around CCRT-Durvalumab. EAMS currently open in England… #BTOG25
March 5, 2025 at 12:19 PM
oncbrothers.bsky.social
2024 approvals: Summary of 14 new drugs/indications in #LungCancer by FDA

1. #Tepotinib
2. #Osimertinib x2
3. #Alectinib
4. #Tarlatamab
5. #Zenocutuzumab
6. #Durvalumab x2
7. #Amivantamab x2
8. #Nivolumab (now SubQ)
9. #Ensartinib

#lcsm #OncSky #MedSky #Cancer
December 28, 2024 at 4:09 PM
mtmdphd.bsky.social
EFS in MATTERHORN: A Ph3 RCT of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin & docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC) - @YJanjigianMD et al. #ASCO25 LBA5 meetings.asco.org/abstracts-pr... #NCT04592913 #stcsm #esocsm
Program Guide – ASCO Meeting Program Guide
meetings.asco.org
April 23, 2025 at 7:24 PM
oncodaily.bsky.social
MATTERHORN Trial at ASCO 2025: Durvalumab plus FLOT Shows Significant Improvement of EFS in Resectable Gastric and GEJ Cancer Treatment
@ascocancer.bsky.social

oncodaily.com/oncolibrary/...

#ASCO #ASCO2025 #CancerResearch #Duvralumab #GastricCancer #MATTERHORNtrial #OncoDaily #Oncology
MATTERHORN Trial at ASCO 2025: Durvalumab plus FLOT Shows Significant Improvement of EFS in Resectable Gastric and GEJ Cancer Treatment - OncoDaily
MATTERHORN trial at ASCO 2025: Durvalumab + FLOT improves event-free survival in resectable gastric cancer, signaling a new standard of care.
oncodaily.com
June 1, 2025 at 9:15 PM
oncodaily.bsky.social
FDA approved Durvalumab plus FLOT for resectable gastric or GEJ adenocarcinoma

@fda.gov

oncodaily.com/fda-approval...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #FDAApproval #Durvalumab
FDA approved Durvalumab plus FLOT for resectable gastric or GEJ adenocarcinoma - OncoDaily
FDA has approved durvalumab in combination with FLOT chemotherapy as neoadjuvant and adjuvant treatment, followed by durva monotherapy.
oncodaily.com
November 26, 2025 at 9:17 PM
oncodaily.bsky.social
DIAmOND Trial at ESMO Breast 2025 Shows Activity of Durvalumab and Tremelimumab in Trastuzumab-Resistant HER2+ Breast Cancer
@myesmo.bsky.social @loisher.bsky.social

oncodaily.com/science/diam...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #DIAmOND #ESMOBreast25
DIAmOND Trial at ESMO Breast 2025 Shows Activity of Durvalumab and Tremelimumab in Trastuzumab-Resistant HER2 Positive Breast Cancer - OncoDaily
Dual checkpoint blockade with tremelimumab + durvalumab shows promise in HER2-positive advanced breast cancer with trastuzumab resistance in the DIAmOND trial at ESMO 2025.
oncodaily.com
May 17, 2025 at 2:36 PM
sodatroubles.bsky.social
Durvalumab-Associated Crescentic Glomerulonephritis with IgA Vasculitis-Like Features
#nephsky
www.kireports.org/article/S246...
Durvalumab-Associated Crescentic Glomerulonephritis with IgA Vasculitis-Like Features
We report a case of IgA vasculitis-like crescentic nephritis induced by durvalumab in a 73-year-old man with limited-stage small cell lung cancer (T1N2M0), treated with etoposide/carboplatin followed ...
www.kireports.org
May 2, 2025 at 2:38 PM
oncodaily.bsky.social
Neoadjuvant durvalumab improves survival in early TNBC independent of pathological complete response

oncodaily.com/insight/206205

#BreastCancer #bcsm #PCR #Medicine #Health #Oncology #OncoDaily #Cancer
Neoadjuvant durvalumab improves survival in early TNBC independent of pathological complete response - OncoDaily
Neoadjuvant durvalumab improves survival in early TNBC independent of pathological complete response / A. Schneeweiss, Akhil Santhosh, Breast Cancer, C.
oncodaily.com
December 17, 2024 at 4:23 PM
findlungcancer.bsky.social
www.fda.gov/drugs/resour... #lcsm
FDA approves durvalumab for limited-stage small cell lung cancer
On December 4, 2024, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) for limited-stage small cell lung cancer (LS-SCLC).
www.fda.gov
December 6, 2024 at 6:51 PM
ducreuxmichel.bsky.social
FLOT + durvalumab new perioperative treatment of localised gastric cancer
June 1, 2025 at 8:24 PM
tiansterzhangmd.bsky.social
#MattGalsky updating results of #NIAGARA - great to see pathologic complete responses from neoadj gem-cis-durvalumab — durva improves disease free & overall survival even in those w pathCR. @ascocancer.bsky.social #GU25
February 14, 2025 at 4:51 PM
ascocancer.bsky.social
5️⃣ Abstract: Dr. Yelena Y. Janjigian with MATTERHORN:
- durvalumab + FLOT in resectable gastric/GEJ cancer.
- EFS NR vs 32.8 months, HR 0.71, p<0.001
- Overall survival not significant with follow-up ongoing
- Adverse events as expected

#ASCO25
June 1, 2025 at 8:28 PM
adesaimd.bsky.social
📢 Breaking news in #SCLC treatment!

Durvalumab is now FDA-approved for limited-stage SCLC based on the ADRIATIC trial. Adding 2 years of durvalumab after chemoradiation improves both PFS and OS (HR 0.73).

This approval marks an important step forward for patients with limited-stage SCLC! 💪
December 5, 2024 at 12:08 AM
oncodaily.bsky.social
ROWAN Study of TheraSphere with Durvalumab and Tremelimumab in HCC Completed Enrollment

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ROWAN #TheraSphere #Durvalumab #Tremelimumab #HCC
ROWAN Study of TheraSphere with Durvalumab and Tremelimumab in HCC Completed Enrollment - OncoDaily
Rowan Study with Durvalumab and Tremelimumab and Therasphere in HCC completed enrollment
oncodaily.com
August 28, 2025 at 1:51 PM
robbrierley.bsky.social
New research - Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study

www.thelancet.com/journals/lan...

@thelancet.bsky.social #LiverSky #OncSky #MedSky
January 9, 2025 at 8:07 AM
oncodaily.bsky.social
DT-Real Study: Real-World Outcomes of Durvalumab With or Without Tremelimumab in Advanced HCC

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Durvalumab #Tremelimumab #HCC
DT-Real Study: Real-World Outcomes of Durvalumab With or Without Tremelimumab in Advanced HCC - OncoDaily
Real-World Outcomes of Durvalumab With or Without Tremelimumab in Advanced HCC of DT-Real Study.
oncodaily.com
November 28, 2025 at 10:56 PM
oncodaily.bsky.social
Real-World Study on Durvalumab in Brazilian Patients with ES-SCLC: EDUR-BRA

oncodaily.com/insight/durv...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Durvalumab #SCLC #ES-SCLC #LungCancer #EDUR-BRA
Real-World Study on Durvalumab in Brazilian Patients with ES-SCLC: EDUR-BRA - OncoDaily
Real-World Study on Durvalumab in Brazilian Patients with ES-SCLC: EDUR-BRA / cancer, Danilo Lopes, Durvalumab, EDUR-BRA, ES-SCLC, LACOG, Latin American
oncodaily.com
September 13, 2025 at 2:17 PM
rdepietro.bsky.social
Interesting data from #STERIMGLI at #EANO2026 on #re-irradiation + #durvalumab for recurrent glioblastoma:

➡️ HF-SRT 24 Gy/3 fx
➡️ Primary OS endpoint not met in ITT population (16.1 vs 13.3 months)
➡️ QoL and cognition maintained
➡️ Exploratory analyses suggest a stronger OS in WHO 2021 glioblastoma
September 27, 2026 at 7:58 AM